{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "earningsTimestamp": 1684181100, "earningsTimestampStart": 1691578740, "earningsTimestampEnd": 1692014400, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -69.76, "epsForward": -3.44, "epsCurrentYear": -5.25, "priceEpsCurrentYear": -0.6971619, "sharesOutstanding": 3731570, "bookValue": 9.658, "fiftyDayAverage": 4.34928, "fiftyDayAverageChange": -0.6891799, "fiftyDayAverageChangePercent": -0.1584584, "twoHundredDayAverage": 9.91144, "twoHundredDayAverageChange": -6.25134, "twoHundredDayAverageChangePercent": -0.63071966, "marketCap": 13657919, "forwardPE": -1.0639825, "priceToBook": 0.3789708, "currency": "USD", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "PRE", "regularMarketChangePercent": -6.8676867, "regularMarketPrice": 3.6601, "firstTradeDateMilliseconds": 1570109400000, "priceHint": 4, "exchange": "NMS", "shortName": "Aprea Therapeutics, Inc.", "longName": "Aprea Therapeutics, Inc.", "messageBoardId": "finmb_329831339", "regularMarketChange": -0.26990008, "regularMarketTime": 1684180465, "regularMarketDayHigh": 3.93, "regularMarketDayRange": "3.65 - 3.93", "regularMarketDayLow": 3.65, "regularMarketVolume": 9299, "regularMarketPreviousClose": 3.93, "bid": 0.0, "ask": 0.0, "bidSize": 10, "askSize": 8, "fullExchangeName": "NasdaqGS", "financialCurrency": "USD", "regularMarketOpen": 3.91, "averageDailyVolume3Month": 15008, "averageDailyVolume10Day": 6150, "fiftyTwoWeekLowChange": 3.1861, "fiftyTwoWeekLowChangePercent": 6.7217298, "fiftyTwoWeekRange": "0.474 - 25.8", "fiftyTwoWeekHighChange": -22.1399, "fiftyTwoWeekHighChangePercent": -0.8581357, "fiftyTwoWeekLow": 0.474, "fiftyTwoWeekHigh": 25.8, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.7 - Buy", "tradeable": false, "cryptoTradeable": false, "displayName": "Aprea Therapeutics", "symbol": "APRE"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "3805 Old Easton Road", "city": "Doylestown", "state": "PA", "zip": "18902", "country": "United States", "phone": "617 463 9385", "website": "https://www.aprea.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.", "fullTimeEmployees": 9, "companyOfficers": [{"maxAge": 1, "name": "Dr. Oren  Gilad Ph.D.", "age": 53, "title": "Co-Founder, CEO, Pres and Director", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 520837, "fmt": "520.84k", "longFmt": "520,837"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. John P. Hamill CPA, CPA", "age": 58, "title": "Sr. VP, CFO, Principal Accounting Officer & Sec.", "yearBorn": 1964, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Dansu  Li Ph.D.", "title": "Head of Technology", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Lars B. Abrahmsen Ph.D.", "age": 65, "title": "Sr. VP & Chief Scientific Officer", "yearBorn": 1957, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Michel  Afargan Ph.D.", "title": "Head of Pharmacology Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Zeev  Weiss B.Sc., C.P.A.", "age": 60, "title": "Chief Bus. Officer", "yearBorn": 1962, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Andrea  Epstein", "title": "Controller", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 6, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}